Home » Stocks » ANIX

Anixa Biosciences, Inc. (ANIX)

Stock Price: $2.78 USD 0.50 (21.93%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $2.95 +0.17 (6.12%) Nov 27, 4:47 PM

Stock Price Chart

Key Info

Market Cap 66.13M
Revenue (ttm) n/a
Net Income (ttm) -9.88M
Shares Out 23.79M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $2.78
Previous Close $2.28
Change ($) 0.50
Change (%) 21.93%
Day's Open 2.28
Day's Range 2.28 - 2.79
Day's Volume 324,104
52-Week Range 1.70 - 3.84

More Stats

Market Cap 66.13M
Enterprise Value 57.14M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.79M
Float 21.34M
EPS (basic) -0.46
EPS (diluted) -0.46
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.15M
Short Ratio 6.19
Short % of Float 5.39%
Beta 1.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.29
Revenue n/a
Operating Income -10.01M
Net Income -9.88M
Free Cash Flow -6.11M
Net Cash 9.00M
Net Cash / Share 0.38
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -74.88%
ROE -147.19%
ROIC -496.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.75*
(214.75% upside)
Low
8.50
Current: $2.78
High
9.00
Target: 8.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.251.110.360.309.263.670.390.941.000.73
Revenue Growth-77.53%206.9%20.83%-96.76%152.36%843.12%-58.63%-6.3%37.3%-
Gross Profit0.080.340.260.085.611.680.070.940.970.65
Operating Income-11.89-14.29-6.08-4.51-0.94-5.04-7.92-4.13-5.03-5.25
Net Income-11.65-14.00-5.01-5.02-1.38-9.61-10.08-4.25-7.38-5.18
Shares Outstanding19.7917.6212.208.748.768.717.877.276.675.94
Earnings Per Share-0.59-0.79-0.58-0.57-0.16-1.10-1.25-0.50-1.00-0.75
Operating Cash Flow-4.74-4.27-3.80-3.381.36-2.38-3.19-3.14-0.72-2.41
Capital Expenditures-0.18-0.040.01-0.15-0.05-0.01---0.01-
Free Cash Flow-4.92-4.31-3.78-3.531.31-2.39-3.19-3.14-0.73-2.41
Cash & Equivalents5.845.066.843.246.775.860.900.843.021.09
Total Debt------5.555.035.005.00
Net Cash / Debt5.845.066.843.246.775.86-4.65-4.19-1.98-3.91
Assets6.296.458.815.639.349.065.445.668.6510.05
Liabilities1.481.270.894.644.285.058.766.857.595.45
Book Value5.245.437.920.995.054.01-3.32-1.191.064.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anixa Biosciences, Inc.
Country United States
Employees 7
CEO Amit D. Kumar

Stock Information

Ticker Symbol ANIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: ANIX
IPO Date January 1, 1987

Description

Anixa Biosciences, a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.